Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
Authors' conclusion
GLP1RA persistence and dosetitration adherence were moderate but weight loss approximated that seen in clinical trials, supporting real-world effectiveness.
Study context
- Population
- Patients aged 18–75 years in a 'no cost to patient' Medical Weight Loss Bundle program at an academic multidisciplinary obesity clinic (January 2022 to December 2024) with ≥1 prescription fill of semaglutide or tirzepatide; median age 46.0 years, 85% femaleof 2855 enrollees
- Participants
- 2,306 patients
- Exposure
- Semaglutide vs Tirzepatide vs Both agents
- Semaglutiden = 1,614
- Tirzepatiden = 117
- Both agentsn = 575
- Outcome
- Persistence with GLP1RA therapy (continuous prescription fills without a gap ≥84 days)
Methodological detailssingle-centre, consecutive patients
- Single-centre
- Consecutive patients
Main finding
As reported in the abstract
Persistence with GLP1RA therapy
Median persistence (IQR 5.4-16.3)
10.7 months
Observational data: associations, not effects.
Further findings
Titration adherence: semaglutide users
- Escalated to ≥1 mg
- 81%
- Escalated to 2.4 mg
- 23%
Titration adherence: tirzepatide users
- Received ≥10 mg
- 75%
- Received 15 mg
- 28%
Weight loss, patients persistent ≥6 months
- Median weight loss (IQR 6.0%-13.4%)
- 9.4%
Weight loss, patients persistent ≥12 months
- Median weight loss (IQR 9.5%-20.5%)
- 14.4%
Original publication
Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes Obes Metab. Published 5 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →